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Introduction
Properties of EPR/alanine dosimetry have been well
documented in numerous reports [1-6]. The recent
development of experimental techniques has allowed to
improve the accuracy and reliability of the method in
low-dose regions (0.5-50 Gy). This allows to perform
accurate measurements in a range of clinical applications
[2-6], such as in phantom dose measurements, external
beam therapy or brachytherapy. EPR/alanine dosimetry is
characterized by high signal stability, tissue equivalence of
energy absorption, flat energy response, applicability to
both photon and particle radiation and nondestructive
readout which render this technique a useful tool in
clinical conditions. Present radiotherapy dosimetric
protocols stress the important role of in vivo dosimetry to
assess the concordance between planned and actually
delivered doses. This is an essential issue in radiotherapy
and determines the final therapeutic effect of this
modality. Discrepancies between prescribed and delivered
doses may increase the risk of complications in case of
overdosing, or reduce the probability tumor control in
case of underdosing. According to ICRU and WHO
recommendations [7-8], the acceptable difference
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A i m.  The aim of this study was to compare radiation doses measured in vivo with the use of ERP/alanine dosimetry with
doses calculated using the CadPlan R.3.1.2 treatment planning system.
M a t e r i a l s  a n d  m e t h o d s.  The doses were measured in vivo using electron paramagnetic resonance (EPR) in L-
alanine. The detectors consisted of small polyethylene bags filled with crystalline L-alanine. Clinical research was performed
on a group of patients undergoing radical and palliative treatment at the Department of Oncology and Radiotherapy of the
Medical University of Gdansk. The planned doses were calculated by the CadPlan R.3.1.2 radiotherapy treatment planning
system.
Re s u l t s.  The average difference between the measured doses and those calculated by the treatment planning system was, for
all 50 fields, 0.6% with a data scatter of 6.3% (standard deviation of a single measurement).
D i s c u s s i o n  a n d  c o n c l u s i o n s.  The results of in vivo dosimetry showed apt concordance between the prescribed and
the actually delivered doses. The 0.6% average difference may be considered satisfactory in routine radiotherapy treatment.
Dozymetria in vivo w teleterapii wiàzkami elektronowymi 
z wykorzystaniem elektronowego rezonansu paramagnetycznego w L-alaninie
C e l  p r a c y.  Celem pracy by∏a ocena dok∏adnoÊci dawek promieniowania podczas teleterapii nowotworów z wykorzystaniem
wiàzek elektronowych.
M a t e r i a ∏ y  i m e t o d y.  Pomiarów in vivo dokonano metodà spektroskopii elektronowego rezonansu paramagnetycznego
(EPR) w L-alaninie. Badania kliniczne obejmowa∏y grup´ pacjentów leczonych radykalnie i paliatywnie w Katedrze i Klinice
Onkologii i Radioterapii Akademii Medycznej w Gdaƒsku. Zastosowano dozymetry w postaci niewielkich saszetek
polietylenowych wype∏nionych krystalicznà L-alaninà. Porównano wyniki pomiarów in vivo z wartoÊciami dawki planowanej
przez komputerowe systemy planowania.
W y n i k i.  Odchylenie Êredniej dawki zmierzonej od zaplanowanej wynosi∏o 0,6%. Odchylenie standardowe pojedynczego
pomiaru wynosi∏o ±6,3%.
W n i o s k i.  Uzyskane wyniki wykaza∏y zgodnoÊç mi´dzy dawkami zmierzonymi a obliczonymi. Ârednie odchylenie pomi´dzy
obydwiema dawkami na poziomie 0,6% mo˝na uznaç za zadowalajàca dla rutynowo prowadzonej radioterapii.
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between delivered and planned doses is 5%. Such
accuracy requires individual treatment planning and
verification of the calculated doses by direct in vivo
measurements.
The aim of the present work was to verify the alanine
dosimetry and its accuracy in clinical in vivo measure-
ments of single fraction radiotherapy doses in patients
treated with high energy electron beams. The measured
doses were compared with those calculated using routine
computer treatment planning systems.
Material and methods
The detectors consisted of small polyethylene bags (16 x 16 mm,
1-3 mm thick) filled with powdered crystalline L-alanine. They
were taped directly to the patients' skin. Some of the detectors
were covered by buildup material (0.5-1 cm layer of tissue-
equivalent gel) and some measured the “skin dose” directly.
The measured one-fraction doses varied from 0.88 Gy to
2.78 Gy. Two detectors measured doses under lead shields. The
measurements included doses from the following fields: post
mastectomy chest wall irradiation, boost to tumor bed, internal
mammary lymph nodes, inguinal lymph nodes and spinal cord.
EPR measurements were performed with Varian E-4 using
1.25 mT modulation amplitude, 5 mW microwave power, 3 s
time constant, 16 min scan.
The detector readings were corrected for variations in SSD
and converted to the reference dose at the maximum dose point
(dmax), using experimentally determined “buildup factor” BF
(Figure 1). Additionally, the detector readings were corrected to
allow for the deviation between the temperature of irradiation
and that during calibration procedure, according to a previously
described protocol [9]. Due to the variations of the average
detector temperature in time, determination of the effective
correction factor k(t) was based on the graphical integration
shown in Figure 2 [9]. Conversion of the corrected EPR signal
Figure 1. Buildup and SSD correction factors applied in data analysis
Figure 2. Determination of temperature correction factor k(t) as a function of irradiation time. The detector
temperature was assumed to be equal to average of thermocouple readings from probes located below and
above the detector attached to patient’s skin
intensity into the absorbed dose was based on calibration of the
alanine detectors using 60Co radiation. Due to the differences (1)
in radiation quality between the calibration beam and the
measured electron beams and (2) in the composition of the
alanine detector and tissue, we performed an additional
conversion of the measured doses and the final dose was







water · (Iel / Iref)
where Deltissue is the dose absorbed in tissue material from the
electron beam, (S/ρ)tissueala stands for the ratio of stopping
powers of tissue and alanine calculated at the actual electron
energy at the measurement point, (µ/ρ)alawater is the ratio of
mass absorption coefficients of alanine and water, Drefwater is
the dose to water in the calibration setup, and Iel/Iref is the ratio
of EPR intensities in the detector and in the reference
(calibration) sample. The sensitivity of alanine detectors to
the dose absorbed from electrons was shown to be constant in
the 6-20 MeV energy range [6]. The total accuracy of dose
measurements was 3.2%, accounting for the precision of EPR
measurements (3%) and the accuracy of the calibration dose
(1%). The doses measured in vivo were compared with the doses
calculated at dmax by the CadPlan R.3.1.2 radiotherapy treatment
planning system. (Varian INC.).
Results
The measured one-fraction doses varied from 0.88 Gy to
2.78 Gy. The results are given in the table as follows:
third column – mean deviation from the planned dose
(averaged over all measured fields for given energy),
fourth column – the standard deviation of the mean
values from third column, fifth column – the scatter of
data reflected by the standard deviation of a single data
point.
The measurements were performed on 50 fields with
+0.6% mean deviation from the RTP dose with
a standard error of a mean value of ±0.9%.
Discussion
The presented results confirm the applicability of
ERP/alanine dosimetry for in vivo monitoring of
radiotherapy doses. The observed 3.2% accuracy at the
single fraction dose level allows for in vivo verification
of actual doses within the recommended 5% accuracy
limit [7, 8]. This dosimetric method hardly affects the
treatment course – the shift in isodose distribution is
approximately 1-3 mm, and occurs only in the field region
below the detector. The application of the detector
prolongs the time for which the patient occupies the
therapeutic table by approximately 10 sec. When
considering the EPR measurement uncertainty and the
scatter of the in vivo measured data, the dosimetry did not
reveal any systematic variations between the planned and
the delivered doses with beam energy (Table I). This
observation is concurrent with the previously observed
flat energy response of alanine detector in the 4-20 MeV
energy range [6]. Despite other sources of deviations,
typical to all in vivo dosimetric methods (e.g. limited
repetition of patient setup), the differences between
theoretical and actual doses observed in the course of
the study can be attributed to the effects related to
nonperpendicular orientation of the beam with regard
to the detector plane, which has not been accounted.
Measurements of “skin dose” are particularly sensitive
to such effects. ERP/alanine dosimetry applied for in vivo
measurements showed similar quantitative results to other
in vivo methods; for example, the reported deviations
between the calculated doses and those measured with
diodes were: in patients undergoing radiation therapy for
head and neck cancer – 0.7% with 2.4% SD and in
patients with prostate cancer +1.4% with 3.5% SD [10].
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